Eden Regulatory News (EDEN)

Eden Research plc ("Eden" or "the Company")

Interim Results for the six months ended 30 June 2012

Eden Research plc, the agrochemical and encapsulation development company, today announces its interim results for the six months ended 30 June 2012.

Business Highlights

·; Further EU regulatory milestone achieved with the receipt by the UK authorities of the draft EFSA conclusion report

·; Exclusive licence agreement signed with Teva Animal Health for animal health applications in North America using Eden's encapsulation technology and terpene formulations with payments of $0.25m made to date, with a further $0.8m due under the agreement

·; Memorandum of Understanding signed with FMC Corporation of the United States, for an exclusive licence for Eden's nematode product in Latin America

·; Data Access and Royalty Agreement signed with Xeda International SA ("Xeda") of France

·; Licence agreement signed with Phytalexin Limited granting exclusive rights to Eden's formulations and encapsulation technologies primarily for use as a head-lice product

·; Patents granted in Australia and ARIPO

Financial Highlights

·; Operating Loss for the period, excluding amortisation, of GBP0.57m (2011: GBP0.40m)

·; Revenue for the period of GBP0.01m (2011: GBP0.02m)

·; Administrative expenses GBP0.35m, excluding AIM listing costs of GBP0.23m (2011: GBP0.41m)

·; Cash at bank GBP0.48m (2011: GBP1.18m)

·; Debt GBP nil (2011: GBP0.63m). All long-term debt converted prior to AIM admission in April 2012

Sir Ben Gill, Non-executive Chairman, said:

"Making the move from the PLUS to the AIM market in May 2012 was, as it transpires, a very timely, but, also significant step forward for Eden which should provide a more well-recognised and dynamic platform upon which to build and expand the business.

Commercially, Eden has made good progress in maximising the potential benefits derived from using its encapsulation technologies in a number of fields of use. The signing of an exclusive licence with Teva Animal Health was a great start to the year which should provide Eden with a significant royalty stream within the next year. To see sales of product using Eden's technologies will be an important milestone in the evolution of the Company.

In February, Eden signed a memorandum of understanding with FMC Corporation ("FMC") for an exclusive licence for Eden's nematode product in Latin America. FMC is one of the world's foremost, diversified chemical companies with leading positions in agricultural, industrial and consumer markets with annual sales of circa US$3.4 billion. FMC recently became one of the world's top ten agro-chemical companies. Eden is also exploring other potential uses for its encapsulation technologies with FMC.

Other agreements signed in the first half of 2012 included a Data Access and Royalty Agreement with Xeda International SA ("Xeda") of France for which Eden will receive royalty payments on sales of Xeda's products which include Thymol as the active ingredient. Also, Eden signed a licence agreement with Phytalexin Limited which granted exclusive rights to Eden's formulations and encapsulation technologies primarily for use as a head-lice product.

Two patents were formally granted during the period which strengthens the real value of Eden's intellectual property and business proposition.

The EU registration process of the three active substances used in Eden's first agrochemical product has passed another key milestone with the recent receipt of the draft European Food Safety Authority Report conclusion. This enables the final part of the process to proceed with the all-important vote expected to take place in Spring 2013.

During the first half of the year and subsequently, Eden has been in dialogue with a number of potential licensees in areas such as food flavourings and cosmetics, as well as for further agrochemical products, such as miticides and powdery and downy mildew.

In line with our business model, the Board continues to seek licensing opportunities which maximise the value of the encapsulation technologies whilst keeping the company streamlined. This involves partnering with companies that have a strong background in their field of expertise and, to this end, we are exploiting a continually growing list of companies that we think are well placed to help us create the most value for our shareholders."

For further information please contact:

Eden Research plc

Consolidated Statement of Financial Position as at 30 June 2012

Eden Research plc

Statement of Changes in Equity as at 30 June 2012

Share Share Merger Warrant Retained

capital premium reserve reserve earnings Total

£ £ £ £ £ £

Six months ended 30 June 2012

Balance at 1 January 2012 993 20,122 10,210 1,434 (27,374) 5,385

Loss and total comprehensive income - - - - (1,492) (1,492)

Transactions with owners

- Issue of share 117 2,231 - - - 2,348

- Options granted - - - 82 (82) -

- Options exercised/lapsed - - - - - -

_______ _______ _______ _______ _______ _______

Transactions with owners 117 2,231 - - - 2,348

_______ _______ _______ _______ _______ _______

Balance at 30 June 2012 1,110 22,353 10,210 1,516 (28,948) 6,241

_______ _______ _______ _______ _______ _______

Six months ended 30 June 2011

Balance at 1 January 2011 670 14,755 10,210 1,254 (24,285) 2,603

Loss and total comprehensive income - - - - (2,222) (2,222)

Transactions with owners

- Issue of shares 323 5,367 - - - 5,690

- Options granted - - - 376 - 376

- Options exercised/lapsed - - - (256) 195 (60)

_______ _______ _______ _______ _______ _______

Transactions with owners 323 5,367 - 180 195 6,0066

_______ _______ _______ _______ _______ _______

Balance at 30 June 2011 993 20,122 10,210 1,374 (26,312) 6,387

_______ _______ _______ _______ _______ _______

Eden Research plc

Statement of cash flows for the six months ended 30 June 2012

Cash and cash equivalents comprise bank account balances.

Notes to the Interim Results

1. The above numbers have not been reviewed by the company's auditors.

2. Nature of operations and general information

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products. Revenues are earned by the Company through identifying suitable industrial partners and entering into licence agreements.

The financial information set out in this interim report does not constitute statutory accounts. The company's statutory financial statements for the year ended 31 December 2011 are available from the company's website. The auditor's report on those financial statements was unqualified.

3. Accounting Policies

Basis of Preparation 

These interim condensed consolidated financial statements are for the six months ended 30 June 2012. They have been prepared following the recognition and measurement principles of IFRS. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the financial statements of the company for the year ended 31 December 2011.

These financial statements have been prepared on the going concern basis and under the historical cost convention.

These condensed consolidated interim financial statements have been prepared in accordance with the accounting policies adopted in the last annual financial statements for the year to 31 December 2011.

The accounting policies have been applied consistently for the purposes of preparation of these condensed interim financial statements.

4. Copies of the interim statement are available from the Company at its registered office, as well as on the Company's website.

5. Loss per share

Loss per share has been calculated on the net basis on the loss after tax of £1,573,877 (30 June 2011: loss £2,221,781), (31 December 2011: £3,283,741) using the weighted average number of ordinary shares in issue of 107,312,913 (30 June 2011 and 31 December 2011: 89,641,547).

Due to the loss for the period there is no dilution of the loss per share arising from options in existence.

6. Intangible assets

Licences

Intellectual and Development

property trademarks Costs Total

£ £ £ £

COST

At 1 January 2011 9,652 290 2,060 12,002

Additions - - 25 25

_________ _________ _________ __________

At 30 June 2011 9,652 290 2,085 12,027

Additions - 129 154 283

_________ _________ _________ __________

At 31 December 2011 9,652 419 2,239 12,310

Additions 28 - 25 53

_________ _________ _________ __________

At 30 June 2012 9,680 419 2,264 12,363

_________ _________ _________ __________

AMORTISATION

At 1 January 2011 3,213 242 350 3,805

Charge for the period 248 14 66 329

__________ _________ _________ __________

At 30 June 2011 3,461 256 416 4,133

Charge for the period 248 14 106 368

__________ _________ _________ __________

At 31 December 2011 3,709 270 522 4,501

Charge for the period 247 15 67 329

__________ _________ _________ __________

At 30 June 2012 3,956 285 589 4,830

__________ _________ _________ __________

CARRYING AMOUNT

At 30 June 2012 5,724 134 1,675 7,533

__________ _________ _________ __________

At 31 December 2011 5,944 149 1,718 7,810

__________ _________ _________ __________

At 30 June 2011 6,191 34 1,669 7,895

__________ _________ _________ __________

At 31 December 2010 6,439 49 1,711 8,198

__________ _________ _________ __________

7. Non-current liabilities

Other payables relate to a non-executory contract which commits the Company to make royalty payments of 2.5% on all future sales that incorporate the main patent to the licensor. The liability has been calculated based on the projected sales forecasts for all products incorporating the main patent discounted to their present value.

8. Share based payments

Share Options

Eden Research plc operates an unapproved option scheme for executive directors, senior management and certain employees.

The exercise price of options outstanding at the end of the period ranged between 10p and 60p (30 June 2011: 9p and 60p) and their weighted average contractual life was 2.6 years (30 June 2011: 3.1 years). None of the options have vesting conditions.

The weighted average share price (at the date of exercise) of options exercised during the period was nil p (30 June 2011: nil p).

The weighted average fair value of each option granted during the period was nil p (30 June 2011: 14p).

The share based payment charge for the period was £81,241 (30 June 2011: £315,267).

Warrants

The exercise price of warrants outstanding at the end of the period ranged between 13p and 21p (30 June 2011: 13p and 21p) and their weighted average contractual life was 1 year (30 June 2011: 1.5 years)

The weighted average share price (at the date of exercise) of warrants exercised during the period was nil p (30 June 2011: 14p).

The weighted average fair value of each warrant granted during the year was 23p (30 June 2011: 17p).

Other notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com